GABARAPL1
Gamma-aminobutyric acid receptor-associated protein-like 1
Protein Summary
Ubiquitin-like modifier that increases cell-surface expression of kappa-type opioid receptor through facilitating anterograde intracellular trafficking of the receptor. Involved in formation of autophagosomal vacuoles. Whereas LC3s are involved in elongation of the phagophore membrane, the GABARAP/GATE-16 subfamily is essential for a later stage in autophagosome maturation.
- ENST00000266458
- ENSP00000266458
- ENSG00000139112
- ENST00000421801
- ENSP00000411256
- ENST00000543602
- ENSP00000445857
- ENST00000545887
- ENSP00000444186
- GEC1
- ATG8
- GEC1
- APG8L
- ATG8B
- ATG8L
- APG8-LIKE
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
hub protein | 1 | ||
disease perturbation | 0.98 | ||
transcription factor perturbation | 0.98 | ||
kinase perturbation | 0.91 | ||
small molecule perturbation | 0.9 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 573.35 (req: < 5)
Gene RIFs: 27 (req: <= 3)
Antibodies: 343 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 573.35 (req: >= 5)
Gene RIFs: 27 (req: > 3)
Antibodies: 343 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 9
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0